FDA new drug approvals in Q3 2021

被引：2

作者：

Urquhart, Lisa ^{[1
]}

机构：

[1] Evaluate Vantage, London, England

来源：

关键词：

D O I：

10.1038/d41573-021-00175-8

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：807 / 807

页数：1

共 50 条

[31] FDA new drug approvals in Q2 2022
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2022, 21 : 550 - 550
[32] FDA new drug approvals in Q1 2020
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2020, 19 : 299 - 299
[33] FDA new drug approvals in Q1 2022
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2022, 21 : 329 - 329
[34] FDA new drug approvals in Q2 2019
Lisa Urquhart
[J]. Nature Reviews Drug Discovery, 2019, 18 : 575 - 575
[35] 2021 FDA approvals
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (02) : 83 - 89
[36] 2021 FDA approvals
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2022, 21 : 83 - 88
[37] FDA Guidance and New Drug Approvals
Walker, Scot
[J]. HOSPITAL PHARMACY, 2018, 53 (06) : 360 - 362
[38] 2021 in review: FDA approvals of new medicines
Kinch, Michael S.
Kraft, Zachary
Schwartz, Tyler
[J]. DRUG DISCOVERY TODAY, 2022, 27 (08) : 2057 - 2064
[39] MARKET WATCH FDA new drug approvals in Q2 2022
Urquhart, Lisa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (08) : 550 - 550
[40] MARKET WATCH FDA new drug approvals in Q2 2019
Urquhart, Lisa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) : 575 - 575